Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Recordati Industria Chimica e Farmaceutica SPA ( (IT:REC) ) has provided an announcement.
Recordati has provided an update on its recently launched share buyback programme, initiated following shareholder approval in April 2025 and intended to supply shares for existing and future stock option and performance share plans for group management. Between 17 and 19 December 2025, the company repurchased 13,050 ordinary shares on the MTA at a weighted average price of €48.3650, bringing its total treasury shareholding to 4,717,290 shares, equal to 2.256% of share capital, a move that supports long-term incentive alignment with management and may influence capital structure and share liquidity over time.
The most recent analyst rating on (IT:REC) stock is a Hold with a EUR50.00 price target. To see the full list of analyst forecasts on Recordati Industria Chimica e Farmaceutica SPA stock, see the IT:REC Stock Forecast page.
More about Recordati Industria Chimica e Farmaceutica SPA
Recordati Industria Chimica e Farmaceutica S.p.A. is an international pharmaceutical group listed on Borsa Italiana, offering treatments in both general and specialist medicine as well as therapies for rare diseases. Operating on a fully integrated model from clinical development to production, marketing and licensing of APIs and finished products, the company serves around 150 countries across EMEA, the Americas and APAC, supported by more than 4,580 employees and a strategic focus on addressing both common and rare conditions.
Average Trading Volume: 262,523
Technical Sentiment Signal: Hold
Current Market Cap: €9.93B
See more data about REC stock on TipRanks’ Stock Analysis page.